CAR T Cell Therapy Progress and Challenges for Solid Tumors
Author:
Publisher
Springer International Publishing
Link
http://link.springer.com/content/pdf/10.1007/978-3-030-38862-1_11
Reference209 articles.
1. Couzin-Frankel J (2013) Breakthrough of the year 2013. Cancer immunotherapy. Science 342(6165):1432–1433
2. Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8(9):1069–1086
3. Darvin P et al (2018) Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 50(12):165
4. Wolchok J (2018) Putting the immunologic brakes on cancer. Cell 175(6):1452–1454
5. Boyiadzis MM et al (2018) Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer 6(1):137
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Targeting ROS-sensing Nrf2 potentiates anti-tumor immunity of intratumoral CD8+ T and CAR-T cells;Molecular Therapy;2024-08
2. Nonsignaling extracellular spacer regulates tumor antigen selectivity of CAR T cells;Molecular Therapy: Oncology;2024-06
3. Extended characterization of anti-CD19 CAR T cell products manufactured at the point of care using the CliniMACS Prodigy system: comparison of donor sources and process duration;Cytotherapy;2024-06
4. Therapeutic potential of CRISPR/CAS9 genome modification in T cell-based immunotherapy of cancer;Cytotherapy;2024-05
5. Novel immunotherapies for breast cancer: Focus on 2023 findings;International Immunopharmacology;2024-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3